Author: PharmaSignal News Desk

Purdue Pharma settlement approved, Sacklers to pay $7 billion over 15 years to address opioid crisis.

Regeneron Eylea HD approvals enhance its market position with two new indications, intensifying competition with Roche’s Vabysmo.

Sarepta FDA warning highlights heart risk in Elevidys therapy, affecting Duchenne muscular dystrophy patients.

Vaccine reformulation proposals could significantly impact manufacturers and access in over 50 countries.

Vaccine Ingredient Ban could impact U.S. childhood vaccine schedule and require costly reformulations.

HIV prevention drug distribution begins in Zambia and Eswatini with 1,000 doses, excluding South Africa.

Trump Kennedy vaccine policy changes could alter the U.S. childhood vaccine schedule, impacting development costs and availability.

Clinical trials access remains limited as only 24% of drugs tested in 89 countries are available post-approval.

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, marking a significant move in the PROTACs technology space.

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, enhancing its cancer treatment pipeline.